Civitas Therapeutics has scored fresh financing en route to potential late-stage development of an inhaled form of levodopa to treat symptoms of Parkinson's disease. Bay City Capital led the $38 million Series B round, which follows the start of a Phase IIb study for the startup's Parkinson's candidate CVT-301.
DRI Capital has put the final pieces together for its $1.45 billion fund to buy drug royalties. Eyeing a range of biopharma companies, academics and inventors, the 21-year old investment group says it's looking to expand on a portfolio of royalties that already includes some top-selling medicines.
Three well-groomed biotech outfits aim to sustain the frenzy for new biotech stocks on Wall Street. This week Acceleron Pharma, Bind Therapeutics and Five Prime Therapeutics proposed price ranges for their planned initial public offerings.
MacroGenics, a developer of next-generation antibodies against cancer and autoimmune diseases, has joined the ranks of biotech companies that either have or plan to hit the public markets this year, seeking up to $60 million in its initial public offering.
When venture investor Jay Lichter developed an inner-ear affliction known as Ménière's disease, the available treatment was so crude and unreliable, he was inspired to fund a new company to come up with a much better commercial product
After taking the helm and pointing South San Francisco-based iPierian in a new direction, CEO Nancy Stagliano today unveiled a $30 million venture round designed to get her crew into the clinic with a lead antibody program, while a separate project is being spun out into a new biotech that she will also direct.
A bullish Sam Waksal hopes to banish the ethical cloud that has hung over his head since doing jail time for the Imclone insider trading scandal with plans to spin some units out into public companies.
Waltham, MA-based Quantia has reeled in $10 million for a Series B round of funding, led by Safeguard Scientifics.
The U.K. biotech Acacia Pharma has won the embrace of some top-shelf venture players willing to step in to fund a late-stage study of its lead drug.
Venture firms have traveled a variety of new routes to limit risks and score returns in biotech, and the Wall Street Journal has covered how Clarus Ventures and OrbiMed Advisors have found potentially lucrative ways of investing in the pipelines of established pharma companies.